{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T14:55:01Z","timestamp":1771512901667,"version":"3.50.1"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2018,10,25]],"date-time":"2018-10-25T00:00:00Z","timestamp":1540425600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2018,10,25]],"date-time":"2018-10-25T00:00:00Z","timestamp":1540425600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1007\/s40263-018-0577-6","type":"journal-article","created":{"date-parts":[[2018,10,25]],"date-time":"2018-10-25T09:48:31Z","timestamp":1540460911000},"page":"1113-1129","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["A Systematic Review of the Efficacy of Cannabinoid Agonist Replacement Therapy for Cannabis Withdrawal Symptoms"],"prefix":"10.1007","volume":"32","author":[{"given":"Maira Aguiar","family":"Werneck","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guilherme Trevizan","family":"Kortas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arthur Guerra","family":"de Andrade","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jo\u00e3o Mauricio","family":"Castaldelli-Maia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,10,25]]},"reference":[{"key":"577_CR1","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1016\/j.drugpo.2014.07.002","volume":"25","author":"S Legleye","year":"2014","unstructured":"Legleye S, Piontek D, Pampel F, Goffette C, Khlat M, Kraus L. Is there a cannabis epidemic model? Evidence from France, Germany and USA. Int J Drug Policy. 2014;25:1103\u201312.","journal-title":"Int J Drug Policy"},{"key":"577_CR2","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s00127-013-0748-1","volume":"49","author":"JM Castaldelli-Maia","year":"2014","unstructured":"Castaldelli-Maia JM, Martins SS, de Oliveira LG, van Laar M, de Andrade AG, Nicastri S. Use transition between illegal drugs among Brazilian university students. Soc Psychiatry Psychiatr Epidemiol. 2014;49:385\u201394.","journal-title":"Soc Psychiatry Psychiatr Epidemiol"},{"key":"577_CR3","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.drugpo.2014.01.017","volume":"25","author":"JJ Palamar","year":"2014","unstructured":"Palamar JJ, Ompad DC, Petkova E. Correlates of intentions to use cannabis among US high school seniors in the case of cannabis legalization. Int J Drug Policy. 2014;25:424\u201335.","journal-title":"Int J Drug Policy"},{"key":"577_CR4","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3389\/fpsyt.2013.00007","volume":"4","author":"JA Crippa","year":"2013","unstructured":"Crippa JA, Hallak JE, Zuardi AW. Marijuana, feijoada and the debate on drug legalization. Front Psychiatry. 2013;4:7.","journal-title":"Front Psychiatry"},{"issue":"S1","key":"577_CR5","doi-asserted-by":"crossref","first-page":"S429","DOI":"10.1111\/dar.12642","volume":"37","author":"JM Cruz","year":"2018","unstructured":"Cruz JM, Boidi MF, Queirolo R. The status of support for cannabis regulation in Uruguay 4\u00a0years after reform: evidence from public opinion surveys. Drug Alcohol Rev. 2018;37(S1):S429\u201334.","journal-title":"Drug Alcohol Rev"},{"key":"577_CR6","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.drugalcdep.2012.12.012","volume":"131","author":"M Vuolo","year":"2013","unstructured":"Vuolo M. National-level drug policy and young people\u2019s illicit drug use: a multilevel analysis of the European Union. Drug Alcohol Depend. 2013;131:149\u201356.","journal-title":"Drug Alcohol Depend"},{"key":"577_CR7","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.drugpo.2014.09.007","volume":"26","author":"B Fischer","year":"2015","unstructured":"Fischer B, Kuganesan S, Room R. Medical Marijuana programs: implications for cannabis control policy\u2014observations from Canada. Int J Drug Policy. 2015;26:15\u20139.","journal-title":"Int J Drug Policy"},{"key":"577_CR8","doi-asserted-by":"crossref","first-page":"120","DOI":"10.2105\/AJPH.2017.304136","volume":"108","author":"SC Fiala","year":"2018","unstructured":"Fiala SC, Dilley JA, Firth CL, Mahler JE. Exposure to marijuana marketing after legalization of retail sales: Oregonians\u2019 experiences, 2015\u20132016. Am J Public Health. 2018;108:120\u20137.","journal-title":"Am J Public Health"},{"key":"577_CR9","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1177\/0091450916667081","volume":"43","author":"MS Subbaraman","year":"2016","unstructured":"Subbaraman MS, Kerr WC. Marijuana policy opinions in Washington state since legalization: would voters vote the same way? Contemp Drug Probl. 2016;43:369\u201380.","journal-title":"Contemp Drug Probl"},{"key":"577_CR10","doi-asserted-by":"crossref","first-page":"359","DOI":"10.3389\/fphar.2016.00359","volume":"7","author":"JA Crippa","year":"2016","unstructured":"Crippa JA, Crippa AC, Hallak JE, Martin-Santos R, Zuardi AW. \u22069-THC Intoxication by cannabidiol-enriched cannabis extract in two children with refractory epilepsy: full remission after switching to purified cannabidiol. Front Pharmacol. 2016;7:359.","journal-title":"Front Pharmacol"},{"key":"577_CR11","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1093\/jat\/30.9.645","volume":"30","author":"D Day","year":"2006","unstructured":"Day D, Kuntz DJ, Feldman M, Presley L. Detection of THCA in oral fluid by GC-MS-MS. J Anal Toxicol. 2006;30:645\u201350.","journal-title":"J Anal Toxicol"},{"key":"577_CR12","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.drugalcdep.2012.08.001","volume":"128","author":"R Vandrey","year":"2013","unstructured":"Vandrey R, Stitzer ML, Mintzer MZ, Huestis MA, Murray JA, Lee D. The dose effects of short-term dronabinol (oral THC) maintenance in daily cannabis users. Drug Alcohol Depend. 2013;128:64\u201370.","journal-title":"Drug Alcohol Depend"},{"key":"577_CR13","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.addbeh.2018.01.008","volume":"81","author":"DW Campbell","year":"2018","unstructured":"Campbell DW, Stewart S, Gray CEP, Ryan CL, Fettes P, McLandress AJ, et al. Chronic cannabis use and attentional bias: extended attentional capture to cannabis cues. Addict Behav. 2018;81:17\u201321.","journal-title":"Addict Behav"},{"key":"577_CR14","doi-asserted-by":"publisher","DOI":"10.1080\/15389588.2018.1500018","author":"D Favretto","year":"2018","unstructured":"Favretto D, Visentin S, Stocchero G, Vogliardi S, Snenghi R, Montisci M (2018) Driving under the influence of drugs: prevalence in road traffic accidents in Italy and considerations on \u201cper se\u201d limits legislation. Traffic Inj Prev. https:\/\/doi.org\/10.1080\/15389588.2018.1500018","journal-title":"Traffic Inj Prev"},{"issue":"14","key":"577_CR15","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1001\/jama.2018.1334","volume":"319","author":"JG Ramaekers","year":"2018","unstructured":"Ramaekers JG. Driving under the influence of cannabis: an increasing public health concern. JAMA. 2018;319(14):1433\u20134.","journal-title":"JAMA"},{"key":"577_CR16","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.jpba.2017.12.059","volume":"151","author":"G Del Balzo","year":"2018","unstructured":"Del Balzo G, Gottardo R, Mengozzi S, Dorizzi RM, Bortolotti F, Appolonova S, et al. \u201cPositive\u201d urine testing for cannabis is associated with increased risk of traffic crashes. J Pharm Biomed Anal. 2018;151:71\u20134.","journal-title":"J Pharm Biomed Anal"},{"issue":"2","key":"577_CR17","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1177\/0748233717733853","volume":"34","author":"E Khashaba","year":"2018","unstructured":"Khashaba E, El-Helaly M, El-Gilany AH, Motawei SM, Foda S. Risk factors for non-fatal occupational injuries among construction workers: a case-control study. Toxicol Ind Health. 2018;34(2):83\u201390.","journal-title":"Toxicol Ind Health"},{"key":"577_CR18","volume-title":"Diagnostic and statistical manual","author":"American Psychiatric Association","year":"2013","unstructured":"American Psychiatric Association. Diagnostic and statistical manual. 5th ed. Arlington: American Psychiatric Association; 2013.","edition":"5"},{"key":"577_CR19","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s40429-017-0143-1","volume":"4","author":"NJ Schlienz","year":"2017","unstructured":"Schlienz NJ, Budney AJ, Lee DC, Vandrey R. Cannabis withdrawal: a review of neurobiological mechanisms and sex differences. Curr Addict Rep. 2017;4:75\u201381.","journal-title":"Curr Addict Rep"},{"issue":"11","key":"577_CR20","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1016\/j.addbeh.2008.02.001","volume":"13","author":"JR Cornelius","year":"2008","unstructured":"Cornelius JR, Chung T, Martin C, Wood DS, Clark DB. Cannabis withdrawal is common among treatment-seeking adolescents with cannabis dependence and major depression, and is associated with rapid relapse to dependence. Addict Behav. 2008;13(11):1500\u20135.","journal-title":"Addict Behav"},{"issue":"1\u20132","key":"577_CR21","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.drugalcdep.2011.06.003","volume":"13","author":"DJ Allsop","year":"2011","unstructured":"Allsop DJ, Norberg MM, Copeland J, Fu S, Budney AJ. The cannabis withdrawal scale development: patterns and predictors of cannabis withdrawal and distress. Drug Alcohol Depend. 2011;13(1\u20132):123\u20139.","journal-title":"Drug Alcohol Depend"},{"issue":"1","key":"577_CR22","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1038\/npp.2017.198","volume":"43","author":"DS Hasin","year":"2018","unstructured":"Hasin DS. US epidemiology of cannabis use and associated problems. Neuropsychopharmacology. 2018;43(1):195\u2013212.","journal-title":"Neuropsychopharmacology"},{"issue":"1","key":"577_CR23","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.drugalcdep.2006.04.014","volume":"13","author":"AJ Budney","year":"2007","unstructured":"Budney AJ, Vandrey RG, Hughes JR, Moore BA, Bahrenburg B. Oral delta-9-tetrahydrocannabinol suppresses cannabis withdrawal symptoms. Drug Alcohol Depend. 2007;13(1):22\u20139.","journal-title":"Drug Alcohol Depend"},{"key":"577_CR24","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1037\/0022-006X.74.2.307","volume":"74","author":"AJ Budney","year":"2006","unstructured":"Budney AJ, Moore BA, Rocha HL, Higgins ST. Clinical trial of abstinence-based vouchers and cognitive-behavioral therapy for cannabis dependence. J Consult Clin Psychol. 2006;74:307\u201316.","journal-title":"J Consult Clin Psychol"},{"issue":"56","key":"577_CR25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta19560","volume":"19","author":"K Cooper","year":"2015","unstructured":"Cooper K, Chatters R, Kaltenthaler E, Wong R. Psychological and psychosocial interventions for cannabis cessation in adults: a systematic review short report. Health Technol Assess. 2015;19(56):1\u2013130.","journal-title":"Health Technol Assess"},{"issue":"2","key":"577_CR26","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s40429-014-0011-1","volume":"1","author":"RE Balter","year":"2014","unstructured":"Balter RE, Cooper ZD, Haney M. Novel pharmacologic approaches to treating cannabis use disorder. Curr Addict Rep. 2014;1(2):137\u201343.","journal-title":"Curr Addict Rep"},{"key":"577_CR27","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1038\/npp.2013.54","volume":"38","author":"M Haney","year":"2013","unstructured":"Haney M, Cooper DZ, Bedi G, Vosburg SK, Comer SD, Foltin RW. Nabilone decreases marijuana withdrawal and a laboratory measure of marijuana relapse. Neuropsychopharmacology. 2013;38:1557\u201365.","journal-title":"Neuropsychopharmacology"},{"key":"577_CR28","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1038\/sj.npp.1300310","volume":"29","author":"M Haney","year":"2004","unstructured":"Haney M, Hart LC, Vosburg KS, Nasser J, Bennet A, Zubaran C, et al. Marijuana withdrawal in humans: effects of oral THC or divalproex. Neuropsychopharmacology. 2004;29:158\u201370.","journal-title":"Neuropsychopharmacology"},{"issue":"3","key":"577_CR29","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1001\/jamapsychiatry.2013.3947","volume":"71","author":"DJ Allsop","year":"2014","unstructured":"Allsop DJ, Copeland J, Linteris N, Dunlop AJ, Montebello M, Sadler C, et al. Nabiximols as agonist replacement therapy during cannabis withdrawal\u2014a randomized clinical trial. JAMA Psychiatry. 2014;71(3):281\u201390.","journal-title":"JAMA Psychiatry"},{"key":"577_CR30","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1097\/FTD.0b013e3182a5c446","volume":"36","author":"G Milman","year":"2014","unstructured":"Milman G, Bergamascchi MM, Lee D, Mendu DR, Barnes AJ, Vandrey R, et al. Plasma cannabinoid concentrations during dronabinol pharmacotherapy for cannabis dependence. Ther Drug Monit. 2014;36:218\u201324.","journal-title":"Ther Drug Monit"},{"issue":"1\u20133","key":"577_CR31","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.drugalcdep.2010.12.010","volume":"116","author":"FR Levin","year":"2011","unstructured":"Levin FR, Mariani JJ, Brooks DJ, Pavlicova M, Cheng W, Nunes E. Dronabinol for treatment of cannabis dependence: a randomized, double-blind, placebo-controlled trial. Drug Alcohol Depend. 2011;116(1\u20133):142\u201350.","journal-title":"Drug Alcohol Depend"},{"issue":"1","key":"577_CR32","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s00213-007-1020-8","volume":"197","author":"M Haney","year":"2008","unstructured":"Haney M, Hart CL, Vosburg SK, Comer SD, Collins S, Foltin RW. Effects of THC and lofexidine in a human laboratory model of marijuana withdrawal and relapse. Psychopharmacology. 2008;197(1):157\u201368.","journal-title":"Psychopharmacology"},{"issue":"3","key":"577_CR33","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s00280-017-3387-5","volume":"80","author":"ME Badowski","year":"2017","unstructured":"Badowski ME. A review of oral cannabinoids and medical marijuana for the treatment of chemotherapy-induced nausea and vomiting: a focus on pharmacokinetic variability and pharmacodynamics. Cancer Chemother Pharmacol. 2017;80(3):441\u20139.","journal-title":"Cancer Chemother Pharmacol"},{"key":"577_CR34","unstructured":"Kim J, Grobelna A. Nabilone for chronic pain management: a review of clinical effectiveness and guidelines. Ottawa: Canadian Agency for Drugs and Technologies in Health; 2017. https:\/\/www.cadth.ca\/media\/pdf\/htis\/oct-2011\/RC0306-000%20Nabilone%20for%20chronic%20pain.pdf. Accessed 20 Sept 2018."},{"key":"577_CR35","doi-asserted-by":"crossref","first-page":"2930","DOI":"10.3390\/ph3092930","volume":"3","author":"NA Darmani","year":"2010","unstructured":"Darmani NA. Mechanisms of broad-spectrum antiemetic efficacy of cannabinoids against chemotherapy-induced acute and delayed vomiting. Pharmaceuticals. 2010;3:2930\u201355.","journal-title":"Pharmaceuticals"},{"issue":"3","key":"577_CR36","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1007\/s00280-017-3257-1","volume":"79","author":"JV Pergolizzi Jr","year":"2017","unstructured":"Pergolizzi JV Jr, Taylor R, LeQuang JA, Zampogna G, Raffa RB. Concise review of the management of iatrogenic emesis using cannabinoids: emphasis on nabilone for chemotherapy-induced nausea and vomiting. Cancer Chemother Pharmacol. 2017;79(3):467\u201377.","journal-title":"Cancer Chemother Pharmacol"},{"key":"577_CR37","unstructured":"Micromedex Solutions. Physicians\u2019 Desk Reference (PDR), 2018. http:\/\/www.micromedexsolutions.com\/micromedex2\/4.46.0\/WebHelp\/MICROMEDEX_2.htm#Document_help\/PDR_document.htm."},{"key":"577_CR38","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1038\/clpt.1980.181","volume":"28","author":"A Ohlsson","year":"1980","unstructured":"Ohlsson A, Lindgren JE, Wahlen A, Agurell S, Hollister LE, Gillespie HK. Plasma delta-9-tetrahydrocannabinol concentrations and clinical effects after oral and intravenous administration and smoking. Clin Pharmacol Ther. 1980;28:409\u201316.","journal-title":"Clin Pharmacol Ther"},{"key":"577_CR39","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1007\/978-1-59745-503-9_13","volume-title":"The cannabinoid receptors","author":"RG Pertwee","year":"2009","unstructured":"Pertwee RG, Thomas A. Therapeutic applications for agents that act at CB1 and CB2 receptors. In: Reggio PH, editor. The cannabinoid receptors. 1st ed. New York: Humana Press; 2009. p. 361\u201392.","edition":"1"},{"key":"577_CR40","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s12035-007-0005-2","volume":"36","author":"RG Pertwee","year":"2007","unstructured":"Pertwee RG. Cannabinoids and multiple sclerosis. Mol Neurobiol. 2007;36:45\u201359.","journal-title":"Mol Neurobiol"},{"issue":"6","key":"577_CR41","doi-asserted-by":"crossref","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","volume":"6","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altan DG, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLOS Med. 2009;6(6):e1000097.","journal-title":"PLOS Med"},{"key":"577_CR42","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","volume":"343","author":"JP Higgins","year":"2011","unstructured":"Higgins JP, Altman DG, G\u00f8tzsche PC, J\u00fcni P, Moher D, Oxman AD, et al. The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928.","journal-title":"BMJ"},{"key":"577_CR43","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.drugalcdep.2015.11.025","volume":"159","author":"FR Levin","year":"2016","unstructured":"Levin FR, Mariani JJ, Pavlicova M, Brooks D, Glass A, Mahony A, et al. Dronabinol and lofexidine for cannabis use disorder: a randomized, double-blind, placebo-controlled trial. Drug Alcohol Depend. 2016;159:53\u201360.","journal-title":"Drug Alcohol Depend"},{"key":"577_CR44","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.drugalcdep.2016.02.020","volume":"161","author":"JM Trigo","year":"2016","unstructured":"Trigo JM, Lagzdins D, Rehm J, Selby P, Gamaleddin I, Fischer B, et al. Effects of fixed or self-titrated dosages of Sativex on cannabis withdrawal and cravings. Drug Alcohol Depend. 2016;161:298\u2013306.","journal-title":"Drug Alcohol Depend"},{"issue":"13","key":"577_CR45","doi-asserted-by":"crossref","first-page":"2469","DOI":"10.1007\/s00213-016-4298-6","volume":"233","author":"ES Herrmann","year":"2016","unstructured":"Herrmann ES, Cooper ZD, Bedi G, Ramesh D, Reed SC, Comer SD, et al. Effects of zolpidem alone and in combination with nabilone on cannabis withdrawal and a laboratory model of relapse in cannabis users. Psychopharmacology. 2016;233(13):2469\u201378.","journal-title":"Psychopharmacology"},{"key":"577_CR46","unstructured":"The European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). European drug report 2015. http:\/\/www.emcdda.europa.eu\/edr2015. Accessed 20 Sept 2018."},{"issue":"3","key":"577_CR47","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1097\/01.yco.0000218592.00689.e5","volume":"13","author":"AJ Budney","year":"2006","unstructured":"Budney AJ, Hughes JR. The cannabis withdrawal syndrome. Curr Opin Psychiatry. 2006;13(3):233\u20138.","journal-title":"Curr Opin Psychiatry"},{"issue":"3","key":"577_CR48","doi-asserted-by":"crossref","first-page":"398","DOI":"10.4088\/JCP.14m09377","volume":"77","author":"L Balda\u00e7ara","year":"2016","unstructured":"Balda\u00e7ara L, Cogo-Moreira H, Parreira BL, Diniz TA, Milhomem JJ, Fernandes CC, et al. Efficacy of topiramate in the treatment of crack cocaine dependence: a double-blind, randomized, placebo-controlled trial. J Clin Psychiatry. 2016;77(3):398\u2013406.","journal-title":"J Clin Psychiatry"},{"issue":"1","key":"577_CR49","doi-asserted-by":"publisher","first-page":"16br02025","DOI":"10.4088\/PCC.16br02025","volume":"19","author":"L Shukla","year":"2017","unstructured":"Shukla L, Bokka S, Shukla T, Kandasamy A, Chand P, Benegal V et al (2017) Benzodiazepine and \u201cZ-drug\u201d dependence: data from a tertiary care center. Prim Care Companion CNS Disord. 2017;19(1):16br02025. https:\/\/doi.org\/10.4088\/PCC.16br02025.","journal-title":"Prim Care Companion CNS Disord"},{"key":"577_CR50","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.eurpsy.2018.02.005","volume":"52","author":"JM Castaldelli-Maia","year":"2018","unstructured":"Castaldelli-Maia JM, Loreto AR, Guimar\u00e3es-Pereira BBS, Carvalho CFC, Gil F, Frallonardo FP, Ismael F, et al. Smoking cessation treatment outcomes among people with and without mental and substance use disorders: an observational real-world study. Eur Psychiatry. 2018;52:22\u20138.","journal-title":"Eur Psychiatry"},{"issue":"4","key":"577_CR51","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1080\/15504263.2017.1328149","volume":"13","author":"AR Loreto","year":"2017","unstructured":"Loreto AR, Carvalho CFC, Frallonardo FP, Ismael F, Andrade AG, Castaldelli-Maia JM. Smoking cessation treatment for patients with mental disorders using CBT and combined pharmacotherapy. J Dual Diagn. 2017;13(4):238\u201346.","journal-title":"J Dual Diagn"}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40263-018-0577-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-018-0577-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-018-0577-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,10]],"date-time":"2021-08-10T17:49:34Z","timestamp":1628617774000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40263-018-0577-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,25]]},"references-count":51,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["577"],"URL":"https:\/\/doi.org\/10.1007\/s40263-018-0577-6","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,25]]},"assertion":[{"value":"25 October 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Dr. Castaldelli-Maia has been awarded a Pfizer Independent Grant for Learning and Change (IGLC) managed by Global Bridges (Healthcare Alliance for Tobacco Dependence Treatment) hosted at the Mayo Clinic, to support free smoking cessation treatment training in addiction\/mental health care units in Brazil (Grant IGLC 13513957) and Portugal (Grant IGLC 25629313), which had no relationship with the present study. Dr. A. G. Andrade is Executive President of the Center for Information on Health and Alcohol (CISA), which had no funding relationship with this project. Dr Werneck and Dr Kortas have no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"There were no funding sources for this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}}]}}